SOURCE: The Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine

October 07, 2015 10:52 ET

The Alliance for Regenerative Medicine Names 32 Member Representatives as New Board of Directors

The Board Will Set the Overall Vision and Direction for the Organization, in Addition to Approving the Annual Budget and Voting on By-Law Amendments

WASHINGTON, DC--(Marketwired - Oct 7, 2015) - The Alliance for Regenerative Medicine (ARM), the international organization representing the gene therapy, cell therapy and tissue engineering sector, announced it has named its new board of directors, effective immediately.

The board's primary responsibilities are to set the overall vision and direction for the organization, in addition to approving the annual budget and voting on any necessary by-law amendments.

"Throughout this process, we've ensured special considerations were made to reflect the diverse focus areas across our membership," said Morrie Ruffin, managing director of ARM. "We welcome this new board and look forward to leveraging their expertise to propel our growing organization forward and continue to promote the sector."

The new board of directors includes ARM's current officers: Edward Lanphier, Chairman; Bob Preti, Vice Chairman; Phil Vanek, Secretary; Claudia Zylberberg, Treasurer.

The board will meet a minimum of three times annually, with at least two of those meetings to be held in-person. There is no set term limit for ARM's board members, however, ARM expects that approximately one-quarter of the board will shift, either during the annual re-election process or owing to voluntary rotation of longest-serving members.

The new board members are as follows:

  • Zami Aberman, CEO, Pluristem Therapeutics
  • Martin Andrews, SVP, Rare Disease Head Unit, GSK
  • Rahul Aras, President and CEO, Juventas
  • Usman Azam, Global Head Cell & Gene Therapies Unit, Novartis
  • Doug Doerfler, President & CEO, MaxCyte
  • Eduardo Bravo, Managing Director and CEO, TiGenix
  • Flagg Flanagan, CEO, DiscGenics
  • Christian Homsy, CEO, Celyad
  • Perry Karsen, CEO, Celgene Cellular Therapeutics
  • Doug Kerr, Senior Director, Neurology Research & Development, Biogen
  • Dena Ladd, Executive Director, Missouri Cures
  • Edward Lanphier, President & CEO, Sangamo BioSciences
  • Michael May, President & CEO, Centre for Commercialization of Regenerative Medicine (CCRM)
  • Randy Mills, President & CEO, California Institute for Regenerative Medicine (CIRM)
  • Matt Patterson, President & CEO, Audentes Therapeutics
  • Steve Paul, President & CEO, Voyager Therapeutics
  • Bob Preti, President & Chief Scientific Officer, PCT, a Caladrius Company
  • Isabelle Riviere, Director, Cell Therapy & Cell Engineering Facility, Memorial Sloan Kettering Cancer Center
  • Martha Rooke, Director, Stem Cell Bioprocessing Group, EMD Millipore Corporation
  • Jay Siegel, Chief Biotechnology Officer and Head, Scientific Strategy, Johnson & Johnson
  • Matthieu Simon, Executive Vice President, Chief Operating Officer, Cellectis
  • Donna Skerrett, Chief Medical Officer, Mesoblast Limited
  • David Smith, Head, Cell Therapy Manufacturing, Lonza
  • Devyn Smith, Head of Strategy for Pharmatherapeutics, Worldwide, Pfizer
  • Doris Taylor, Director, Regenerative Medicine Research, Texas Heart Institute
  • Keith Thompson, CEO, UK Cell Therapy Catapult
  • Gil Van Bokkelen, Chairman and CEO, Athersys
  • Phil Vanek, General Manager, Cell BioProcessing, GE Healthcare
  • Alexander Vos, CEO, PharmaCell
  • Jeff Walsh, COO, bluebird bio
  • Susan Washer, CEO, AGCT
  • Claudia Zylberberg, Founder and CEO, Akron Biotechnology, LLC

About The Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 225 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.

Contact Information